Akili, Inc. (AKLI) Stock Competitors & Peer Comparison

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, BTSGU has a market cap of 39.4B. Regarding current trading prices, AKLI is priced at $0.43, while BTSGU trades at $201.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas BTSGU's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to BTSGU's ROE of +0.13%. Regarding short-term risk, AKLI is less volatile compared to BTSGU. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check BTSGU's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, GEHC has a market cap of 30B. Regarding current trading prices, AKLI is priced at $0.43, while GEHC trades at $64.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas GEHC's P/E ratio is 15.83. In terms of profitability, AKLI's ROE is -0.70%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, AKLI is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check GEHC's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, VEEV has a market cap of 27.4B. Regarding current trading prices, AKLI is priced at $0.43, while VEEV trades at $165.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas VEEV's P/E ratio is 29.73. In terms of profitability, AKLI's ROE is -0.70%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, AKLI is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check VEEV's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, AKLI is priced at $0.43, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas GEHCV's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, AKLI is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check GEHCV's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, BTSG has a market cap of 11.8B. Regarding current trading prices, AKLI is priced at $0.43, while BTSG trades at $60.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas BTSG's P/E ratio is 79.22. In terms of profitability, AKLI's ROE is -0.70%, compared to BTSG's ROE of +0.13%. Regarding short-term risk, AKLI is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check BTSG's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, AKLI is priced at $0.43, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SGFY's P/E ratio is 70.91. In terms of profitability, AKLI's ROE is -0.70%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, AKLI is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check SGFY's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, TEM has a market cap of 8.5B. Regarding current trading prices, AKLI is priced at $0.43, while TEM trades at $50.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas TEM's P/E ratio is -28.38. In terms of profitability, AKLI's ROE is -0.70%, compared to TEM's ROE of -0.70%. Regarding short-term risk, AKLI is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check TEM's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, HQY has a market cap of 7.5B. Regarding current trading prices, AKLI is priced at $0.43, while HQY trades at $89.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas HQY's P/E ratio is 33.42. In terms of profitability, AKLI's ROE is -0.70%, compared to HQY's ROE of +0.11%. Regarding short-term risk, AKLI is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check HQY's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, AKLI is priced at $0.43, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas RCM's P/E ratio is -102.21. In terms of profitability, AKLI's ROE is -0.70%, compared to RCM's ROE of +0.00%. Regarding short-term risk, AKLI is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check RCM's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, HNGE has a market cap of 4.9B. Regarding current trading prices, AKLI is priced at $0.43, while HNGE trades at $63.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas HNGE's P/E ratio is -7.05. In terms of profitability, AKLI's ROE is -0.70%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, AKLI is less volatile compared to HNGE. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check HNGE's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, TXG has a market cap of 3.9B. Regarding current trading prices, AKLI is priced at $0.43, while TXG trades at $29.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas TXG's P/E ratio is -179.94. In terms of profitability, AKLI's ROE is -0.70%, compared to TXG's ROE of -0.03%. Regarding short-term risk, AKLI is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check TXG's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, DOCS has a market cap of 3.8B. Regarding current trading prices, AKLI is priced at $0.43, while DOCS trades at $20.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas DOCS's P/E ratio is 20.87. In terms of profitability, AKLI's ROE is -0.70%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, AKLI is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check DOCS's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, AKLI is priced at $0.43, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ONEM's P/E ratio is -7.77. In terms of profitability, AKLI's ROE is -0.70%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, AKLI is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check ONEM's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, PRVA has a market cap of 2.8B. Regarding current trading prices, AKLI is priced at $0.43, while PRVA trades at $22.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas PRVA's P/E ratio is 130.41. In terms of profitability, AKLI's ROE is -0.70%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, AKLI is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check PRVA's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, AKLI is priced at $0.43, while HTFL trades at $29.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas HTFL's P/E ratio is -9.28. In terms of profitability, AKLI's ROE is -0.70%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, AKLI is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check HTFL's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, AKLI is priced at $0.43, while PINC trades at $28.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas PINC's P/E ratio is 166.24. In terms of profitability, AKLI's ROE is -0.70%, compared to PINC's ROE of -0.02%. Regarding short-term risk, AKLI is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check PINC's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, AKLI is priced at $0.43, while PGNY trades at $25.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas PGNY's P/E ratio is 33.55. In terms of profitability, AKLI's ROE is -0.70%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, AKLI is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check PGNY's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, OMCL has a market cap of 1.9B. Regarding current trading prices, AKLI is priced at $0.43, while OMCL trades at $38.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas OMCL's P/E ratio is 92.48. In terms of profitability, AKLI's ROE is -0.70%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, AKLI is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check OMCL's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, WGS has a market cap of 1.7B. Regarding current trading prices, AKLI is priced at $0.43, while WGS trades at $55.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas WGS's P/E ratio is -21.18. In terms of profitability, AKLI's ROE is -0.70%, compared to WGS's ROE of -0.28%. Regarding short-term risk, AKLI is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check WGS's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, AKLI is priced at $0.43, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas NXGN's P/E ratio is -266.00. In terms of profitability, AKLI's ROE is -0.70%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, AKLI is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check NXGN's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, AKLI is priced at $0.43, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas AGTI's P/E ratio is -71.79. In terms of profitability, AKLI's ROE is -0.70%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, AKLI is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check AGTI's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, AKLI is priced at $0.43, while TDOC trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas TDOC's P/E ratio is -7.15. In terms of profitability, AKLI's ROE is -0.70%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, AKLI is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check TDOC's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, OMDA has a market cap of 1.1B. Regarding current trading prices, AKLI is priced at $0.43, while OMDA trades at $17.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas OMDA's P/E ratio is -79.65. In terms of profitability, AKLI's ROE is -0.70%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, AKLI is less volatile compared to OMDA. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check OMDA's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SDGR has a market cap of 1.1B. Regarding current trading prices, AKLI is priced at $0.43, while SDGR trades at $14.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SDGR's P/E ratio is -10.37. In terms of profitability, AKLI's ROE is -0.70%, compared to SDGR's ROE of -0.31%. Regarding short-term risk, AKLI is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SDGR's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, GDRX has a market cap of 918.6M. Regarding current trading prices, AKLI is priced at $0.43, while GDRX trades at $2.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas GDRX's P/E ratio is 44.17. In terms of profitability, AKLI's ROE is -0.70%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, AKLI is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check GDRX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, AKLI is priced at $0.43, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CCLDO's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, AKLI is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check CCLDO's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, NUTX has a market cap of 806.2M. Regarding current trading prices, AKLI is priced at $0.43, while NUTX trades at $133.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas NUTX's P/E ratio is 9.90. In terms of profitability, AKLI's ROE is -0.70%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, AKLI is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check NUTX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CERT has a market cap of 805.8M. Regarding current trading prices, AKLI is priced at $0.43, while CERT trades at $5.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CERT's P/E ratio is -51.80. In terms of profitability, AKLI's ROE is -0.70%, compared to CERT's ROE of -0.01%. Regarding short-term risk, AKLI is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check CERT's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, HSTM has a market cap of 759.6M. Regarding current trading prices, AKLI is priced at $0.43, while HSTM trades at $26.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas HSTM's P/E ratio is 38.81. In terms of profitability, AKLI's ROE is -0.70%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, AKLI is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check HSTM's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, AKLI is priced at $0.43, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, AKLI is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check MPLN-WT's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, AKLI is priced at $0.43, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ACCD's P/E ratio is -3.08. In terms of profitability, AKLI's ROE is -0.70%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, AKLI is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check ACCD's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, PHR has a market cap of 574.9M. Regarding current trading prices, AKLI is priced at $0.43, while PHR trades at $9.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas PHR's P/E ratio is 58.13. In terms of profitability, AKLI's ROE is -0.70%, compared to PHR's ROE of +0.03%. Regarding short-term risk, AKLI is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check PHR's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, AKLI is priced at $0.43, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SHCR's P/E ratio is -3.76. In terms of profitability, AKLI's ROE is -0.70%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, AKLI is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check SHCR's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, EVH has a market cap of 531.5M. Regarding current trading prices, AKLI is priced at $0.43, while EVH trades at $4.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas EVH's P/E ratio is -1.01. In terms of profitability, AKLI's ROE is -0.70%, compared to EVH's ROE of -0.78%. Regarding short-term risk, AKLI is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check EVH's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CTEV has a market cap of 483.6M. Regarding current trading prices, AKLI is priced at $0.43, while CTEV trades at $29.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CTEV's P/E ratio is -1.64. In terms of profitability, AKLI's ROE is -0.70%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, AKLI is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check CTEV's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, NRC has a market cap of 445.1M. Regarding current trading prices, AKLI is priced at $0.43, while NRC trades at $20.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas NRC's P/E ratio is 50.64. In terms of profitability, AKLI's ROE is -0.70%, compared to NRC's ROE of +0.57%. Regarding short-term risk, AKLI is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check NRC's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, AKLI is priced at $0.43, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SLGC's P/E ratio is -3.04. In terms of profitability, AKLI's ROE is -0.70%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, AKLI is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SLGC's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, AKLI is priced at $0.43, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, AKLI's ROE is -0.70%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, AKLI is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SLGCW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, TBRG has a market cap of 390M. Regarding current trading prices, AKLI is priced at $0.43, while TBRG trades at $26.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas TBRG's P/E ratio is 89.66. In terms of profitability, AKLI's ROE is -0.70%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, AKLI is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check TBRG's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SOPH has a market cap of 387M. Regarding current trading prices, AKLI is priced at $0.43, while SOPH trades at $5.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SOPH's P/E ratio is -4.58. In terms of profitability, AKLI's ROE is -0.70%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, AKLI is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SOPH's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, AKLI is priced at $0.43, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas MPLN's P/E ratio is -0.23. In terms of profitability, AKLI's ROE is -0.70%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, AKLI is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check MPLN's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SLP has a market cap of 323.5M. Regarding current trading prices, AKLI is priced at $0.43, while SLP trades at $16.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SLP's P/E ratio is -5.13. In terms of profitability, AKLI's ROE is -0.70%, compared to SLP's ROE of -0.49%. Regarding short-term risk, AKLI is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SLP's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CARL has a market cap of 306.9M. Regarding current trading prices, AKLI is priced at $0.43, while CARL trades at $11.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CARL's P/E ratio is -11.52. In terms of profitability, AKLI's ROE is -0.70%, compared to CARL's ROE of -0.62%. Regarding short-term risk, AKLI is less volatile compared to CARL. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check CARL's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, AKLI is priced at $0.43, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas TRHC's P/E ratio is -4.27. In terms of profitability, AKLI's ROE is -0.70%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, AKLI is less volatile compared to TRHC. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check TRHC's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, AKLI is priced at $0.43, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SMFR's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, AKLI is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SMFR's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SY has a market cap of 244.1M. Regarding current trading prices, AKLI is priced at $0.43, while SY trades at $1.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SY's P/E ratio is -4.89. In terms of profitability, AKLI's ROE is -0.70%, compared to SY's ROE of -0.16%. Regarding short-term risk, AKLI is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SY's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SPOK has a market cap of 224.5M. Regarding current trading prices, AKLI is priced at $0.43, while SPOK trades at $10.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SPOK's P/E ratio is 18.22. In terms of profitability, AKLI's ROE is -0.70%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, AKLI is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SPOK's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, AMWL has a market cap of 142M. Regarding current trading prices, AKLI is priced at $0.43, while AMWL trades at $8.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas AMWL's P/E ratio is -1.57. In terms of profitability, AKLI's ROE is -0.70%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, AKLI is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check AMWL's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, AKLI is priced at $0.43, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CPSI's P/E ratio is -183.80. In terms of profitability, AKLI's ROE is -0.70%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, AKLI is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check CPSI's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, HCAT has a market cap of 126.4M. Regarding current trading prices, AKLI is priced at $0.43, while HCAT trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas HCAT's P/E ratio is -0.46. In terms of profitability, AKLI's ROE is -0.70%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, AKLI is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check HCAT's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, AKLI is priced at $0.43, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas AUGX's P/E ratio is -4.99. In terms of profitability, AKLI's ROE is -0.70%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, AKLI is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check AUGX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CCLD has a market cap of 101.6M. Regarding current trading prices, AKLI is priced at $0.43, while CCLD trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CCLD's P/E ratio is 18.38. In terms of profitability, AKLI's ROE is -0.70%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, AKLI is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check CCLD's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, OPRX has a market cap of 95.1M. Regarding current trading prices, AKLI is priced at $0.43, while OPRX trades at $5.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas OPRX's P/E ratio is 14.08. In terms of profitability, AKLI's ROE is -0.70%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, AKLI is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check OPRX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, DH has a market cap of 89.7M. Regarding current trading prices, AKLI is priced at $0.43, while DH trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas DH's P/E ratio is -0.51. In terms of profitability, AKLI's ROE is -0.70%, compared to DH's ROE of -0.67%. Regarding short-term risk, AKLI is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check DH's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, AKLI is priced at $0.43, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas FORA's P/E ratio is -24.11. In terms of profitability, AKLI's ROE is -0.70%, compared to FORA's ROE of -0.17%. Regarding short-term risk, AKLI is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check FORA's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, AKLI is priced at $0.43, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CCLDP's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, AKLI is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check CCLDP's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ONMD has a market cap of 35.1M. Regarding current trading prices, AKLI is priced at $0.43, while ONMD trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ONMD's P/E ratio is -16.13. In terms of profitability, AKLI's ROE is -0.70%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, AKLI is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check ONMD's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, AKLI is priced at $0.43, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SNCE's P/E ratio is -0.27. In terms of profitability, AKLI's ROE is -0.70%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, AKLI is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check SNCE's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, AKLI is priced at $0.43, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SHLT's P/E ratio is -3.87. In terms of profitability, AKLI's ROE is -0.70%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, AKLI is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check SHLT's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, AKLI is priced at $0.43, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, AKLI's ROE is -0.70%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, AKLI is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SHCRW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ONMDW has a market cap of 30.3M. Regarding current trading prices, AKLI is priced at $0.43, while ONMDW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ONMDW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, AKLI is less volatile compared to ONMDW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check ONMDW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, EUDA has a market cap of 29.5M. Regarding current trading prices, AKLI is priced at $0.43, while EUDA trades at $15.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas EUDA's P/E ratio is -10.68. In terms of profitability, AKLI's ROE is -0.70%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, AKLI is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check EUDA's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, BEAT has a market cap of 27.1M. Regarding current trading prices, AKLI is priced at $0.43, while BEAT trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas BEAT's P/E ratio is -1.40. In terms of profitability, AKLI's ROE is -0.70%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, AKLI is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check BEAT's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, AKLI is priced at $0.43, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas STRM's P/E ratio is -2.40. In terms of profitability, AKLI's ROE is -0.70%, compared to STRM's ROE of -0.32%. Regarding short-term risk, AKLI is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check STRM's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, AKLI is priced at $0.43, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas RNLX's P/E ratio is -0.33. In terms of profitability, AKLI's ROE is -0.70%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, AKLI is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check RNLX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, AKLI is priced at $0.43, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas LIFW's P/E ratio is -0.02. In terms of profitability, AKLI's ROE is -0.70%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, AKLI is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check LIFW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, AKLI is priced at $0.43, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas BBLN's P/E ratio is -0.04. In terms of profitability, AKLI's ROE is -0.70%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, AKLI is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check BBLN's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, AKLI is priced at $0.43, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ETAO's P/E ratio is -0.01. In terms of profitability, AKLI's ROE is -0.70%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, AKLI is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check ETAO's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, BFRG has a market cap of 7.1M. Regarding current trading prices, AKLI is priced at $0.43, while BFRG trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas BFRG's P/E ratio is -1.24. In terms of profitability, AKLI's ROE is -0.70%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, AKLI is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check BFRG's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, AKLI is priced at $0.43, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas HLTH's P/E ratio is -0.02. In terms of profitability, AKLI's ROE is -0.70%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, AKLI is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check HLTH's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, SCNX has a market cap of 5.6M. Regarding current trading prices, AKLI is priced at $0.43, while SCNX trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas SCNX's P/E ratio is -0.15. In terms of profitability, AKLI's ROE is -0.70%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, AKLI is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check SCNX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, AKLI is priced at $0.43, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, AKLI is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check UPH-WT's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, AKLI is priced at $0.43, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas UPH's P/E ratio is -0.07. In terms of profitability, AKLI's ROE is -0.70%, compared to UPH's ROE of -1.05%. Regarding short-term risk, AKLI is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check UPH's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, AKLI is priced at $0.43, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas PEAR's P/E ratio is -0.08. In terms of profitability, AKLI's ROE is -0.70%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, AKLI is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check PEAR's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, AKLI is priced at $0.43, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas PEARW's P/E ratio is -0.00. In terms of profitability, AKLI's ROE is -0.70%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, AKLI is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check PEARW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, MGRX has a market cap of 3.5M. Regarding current trading prices, AKLI is priced at $0.43, while MGRX trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas MGRX's P/E ratio is -0.27. In terms of profitability, AKLI's ROE is -0.70%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, AKLI is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check MGRX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, VSEEW has a market cap of 2.8M. Regarding current trading prices, AKLI is priced at $0.43, while VSEEW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas VSEEW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, AKLI is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check VSEEW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, HCTI has a market cap of 2.7M. Regarding current trading prices, AKLI is priced at $0.43, while HCTI trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas HCTI's P/E ratio is 0.01. In terms of profitability, AKLI's ROE is -0.70%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, AKLI is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check HCTI's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, VSEE has a market cap of 2.6M. Regarding current trading prices, AKLI is priced at $0.43, while VSEE trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas VSEE's P/E ratio is -0.29. In terms of profitability, AKLI's ROE is -0.70%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, AKLI is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check VSEE's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, AKLI is priced at $0.43, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas OTRK's P/E ratio is -0.02. In terms of profitability, AKLI's ROE is -0.70%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, AKLI is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check OTRK's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, BEATW has a market cap of 2M. Regarding current trading prices, AKLI is priced at $0.43, while BEATW trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas BEATW's P/E ratio is -0.12. In terms of profitability, AKLI's ROE is -0.70%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, AKLI is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check BEATW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, BFRGW has a market cap of 1.9M. Regarding current trading prices, AKLI is priced at $0.43, while BFRGW trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas BFRGW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, AKLI is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check BFRGW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ACON has a market cap of 1.7M. Regarding current trading prices, AKLI is priced at $0.43, while ACON trades at $3.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ACON's P/E ratio is -0.58. In terms of profitability, AKLI's ROE is -0.70%, compared to ACON's ROE of -0.54%. Regarding short-term risk, AKLI is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check ACON's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, AKLI is priced at $0.43, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CMAX's P/E ratio is -0.00. In terms of profitability, AKLI's ROE is -0.70%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, AKLI is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check CMAX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, AKLI is priced at $0.43, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, AKLI is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check LIFWZ's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, EUDAW has a market cap of 952.7K. Regarding current trading prices, AKLI is priced at $0.43, while EUDAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas EUDAW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, AKLI is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check EUDAW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, AKLI is priced at $0.43, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, AKLI is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check MSPRZ's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, MSPR has a market cap of 304.4K. Regarding current trading prices, AKLI is priced at $0.43, while MSPR trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas MSPR's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, AKLI is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check MSPR's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, AKLI is priced at $0.43, while WORX trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas WORX's P/E ratio is -0.20. In terms of profitability, AKLI's ROE is -0.70%, compared to WORX's ROE of -0.65%. Regarding short-term risk, AKLI is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check WORX's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, AKLI is priced at $0.43, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas KERNW's P/E ratio is -0.00. In terms of profitability, AKLI's ROE is -0.70%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, AKLI is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check KERNW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, AKLI is priced at $0.43, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas KERN's P/E ratio is -0.01. In terms of profitability, AKLI's ROE is -0.70%, compared to KERN's ROE of -0.17%. Regarding short-term risk, AKLI is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check KERN's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, WGSWW has a market cap of 147.6K. Regarding current trading prices, AKLI is priced at $0.43, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas WGSWW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, AKLI is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check WGSWW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ZCMD has a market cap of 81.3K. Regarding current trading prices, AKLI is priced at $0.43, while ZCMD trades at $0.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ZCMD's P/E ratio is -0.01. In terms of profitability, AKLI's ROE is -0.70%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, AKLI is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check ZCMD's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, AKLI is priced at $0.43, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas LIFWW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, AKLI is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check LIFWW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, AKLI is priced at $0.43, while OTRKP trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, AKLI's ROE is -0.70%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, AKLI is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check OTRKP's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, AKLI is priced at $0.43, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas CMAXW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, AKLI is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check CMAXW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, MSPRW has a market cap of 26.2K. Regarding current trading prices, AKLI is priced at $0.43, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas MSPRW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, AKLI is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check MSPRW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ACONW has a market cap of 15.6K. Regarding current trading prices, AKLI is priced at $0.43, while ACONW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ACONW's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, AKLI is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for AKLI.Check ACONW's competition here

AKLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AKLI stands at 34.1M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, AKLI is priced at $0.43, while ICCT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AKLI currently has a P/E ratio of -0.71, whereas ICCT's P/E ratio is N/A. In terms of profitability, AKLI's ROE is -0.70%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, AKLI is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for AKLI.Check ICCT's competition here